Meeting
2012 ASCO Annual Meeting
Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed/refractory multiple myeloma (MM): A phase I study.
Authors
Shaji Kumar
Mayo Clinic, Rochester, MN
Shaji Kumar , William Bensinger , Craig B. Reeder , Todd M. Zimmerman , James R. Berenson , Guohui Liu , Deborah Berg , Neeraj Gupta , Alessandra Di Bacco , Ai-Min Hui , Ruben Niesvizky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT00963820
Citation
J Clin Oncol 30, 2012 (suppl; abstr 8034)
DOI
10.1200/jco.2012.30.15_suppl.8034
Abstract #
8034
Poster Bd #
14
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM).
First Author: Dan T. Vogl
Poster
2013 ASCO Annual Meeting
Phase I study of TH-302, an investigational hypoxia-targeted drug, and dexamethasone in patients with relapsed/refractory multiple myeloma.
First Author: Irene M. Ghobrial
Poster
2015 ASCO Annual Meeting
Updated results from CHAMPION-1, a phase I/II study investigating weekly carfilzomib with dexamethasone for patients (Pts) with relapsed or refractory multiple myeloma (RRMM).
First Author: James R. Berenson
Poster
2014 ASCO Annual Meeting
A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM).
First Author: David H. Vesole